Elmar Joura (Austria)

Medical University Vienna Gynecologic Oncology
Dr. Joura graduated from University of Graz, Austria where he subsequently worked at the Department of Pathological Anatomy. After internship of urology, surgery and internal Medicine, he started his training in Obstetrics and Gynecology, at the University of Vienna. Before he finished specialization, he worked for a period in Tanzania. Subsequently, he focused on gynecologic oncology and received a scholarship for a study leave at the National Women´s Hospital in Auckland, New Zealand. Since 1997 Dr. Joura is consultant gynecological oncologist and in 1998 he made his thesis on epithelial disorders of the vulva. Dr. Joura is head of the clinic for colposcopy and vulvar disease, is consultant for pelvic surgery and was involved in the development of different surgical techniques. Since 2001 Dr. Joura is investigator for the quadrivalent HPV vaccine trials, he has become member of publishing committee and the Global Advisory Board. He is also member of the Scientific Advisory Board and coordinating investigator for the ninevalent HPV vaccine. He is president of the European college for the study of vulvovaginal disease (ECSVD) from 2018-20. Dr. Joura has published more than 140 articles in peer- review journals and given more than 1000 lectures worldwide.

Presenter of 2 Presentations

Clinical Research / Prophylactic Vaccines – Clinical Aspects ePoster

HPV VACCINATION PROTECTS AGAINST HPV INFECTION AND DISEASE IN SEXUALLY ACTIVE ADULTS: A REVIEW OF QUADRIVALENT HPV VACCINE CLINICAL TRIALS (ID 1302)

Session Date
07/21/2020
Session Time
10:00 - 17:00
Room
ePoster
Session Type
Poster Viewing - 20-24 July
Session Name
Clinical Research / Prophylactic Vaccines – Clinical Aspects
Lecture Time
10:00 - 10:01

Abstract

Introduction

The quadrivalent HPV (qHPV) vaccine clinical program included sexually active females regardless of baseline HPV status. Therefore, per-protocol efficacy analyses for each vaccine HPV type (HPV6/11/16/18) included participants infected by other vaccine or non-vaccine HPV types. The qHPV vaccine demonstrated consistently high clinical efficacy in females aged 16–45 years. The vaccine is prophylactic, without efficacy against disease caused by HPV types present before vaccination.

Methods

We summarize data from the randomized, placebo-controlled, double-blind, international FUTURE I (NCT00092521), II (NCT00092534), and III (NCT00090220) qHPV vaccine studies in females aged 16–26 (N=17,622; FUTURE I and II) and 24–45 years (N=3819; FUTURE III). HPV DNA positivity was a surrogate for current infection; anti-HPV seropositivity and HPV DNA negativity was a surrogate for past infection.

Results

Clinical trial data indicate that infection with all vaccine HPV types is rare: 0.1% of 3578 North American females were positive for all four qHPV vaccine types by serology and/or HPV DNA; none were infected with all 9-valent HPV vaccine types. Most prevalent HPV infections in females aged 16–25 years consist of only one or two high-risk HPV types (Barr, Am J Obstet Gynecol 2008). In FUTURE I and II participants infected with 1–3 vaccine HPV types, the qHPV vaccine protected against HPV-related cervical and external genital disease caused by the remaining HPV types (FUTURE II Study Group, J Infect Dis 2007). The qHPV vaccine also prevented cervical and external genital disease in females aged 16–26 years and persistent infection in females 27–45 years regardless of previous exposure to vaccine HPV types (Olsson, Human Vaccines 2009; Castellsague, Br J Cancer 2011).

Conclusions

HPV vaccination can protect against HPV infection and disease in adults previously infected with HPV. Vaccination should not be withheld from sexually active individuals with prior HPV exposure.

Hide
Oral Session 3: Clinical Aspects of Cervical Prevention and Treatment Hall C

IMMUNOGENICITY AND SAFETY OF A NINE-VALENT HUMAN PAPILLOMAVIRUS VACCINE IN WOMEN AGED 27–45 YEARS VERSUS 16–26 YEARS: AN OPEN-LABEL PHASE 3 TRIAL (ID 1306)

Webcast

[session]
[presentation]
[presenter]
Hide

Moderator of 1 Session

Clinical Science Oral Session
Session Type
Clinical Science Oral Session
Session Date
07/22/2020
Session Time
07:45 - 08:35
Room
Hall C

Session Webcast